米国国立癌研究所の了解覚書
MEMORANDUM OF UNDERSTANDING between [Source Country Organization]
and THE DEVELOPMENTAL THERAPEUTICS PROGRAM DIVISION OF CANCER
TREATMENT AND DIAGNOSIS NATIONAL CANCER INSTITUTE
資源提供国の組織（SCO）と米国国立癌研究所癌治療・診断部門創薬プログラムとの了解覚書

遺伝資源提供国と良好な関係を保ちつつ、遺伝資源の産業利用を図るためには、資源提供国と資源利用国の間でABSに関するベストプラクティスモデルを構築することが有効となる。
2004 年、産業界専門家及び学識経験者からなる「遺伝資源へのアクセスと利益配分に関するタスクフォース）の下で、CBD 及びボン・ガイドラインにのっとった実用性と機能性に富むツールとして「遺伝資源へのアクセス手引」（経済産業省及び JBA 版、2005 年 3 月発行）が作成された。この手引は海外遺伝資源の利用者にとって非常に役立つものであり、CBD/
ABS に取り組む際のベストプラクティスとして、発行以来多くの関係者に活用されてきた。
2012 年 3 月には、この初版「遺伝資源へのアクセス手引」に名古屋議定書の重要原則を導入し、手引第2版を発行した。
平成 24 年度経済産業省委託事業では国内産業の実情を踏まえ、JBA が開設する ABS 相談窓
口で多く寄せられた質問や要望（「相互に合意する条件」の事例にはどのようなものがあるか）に答えるため、この手引に契約書の作成例として、米国国立癌研究所（National Cancer Institute、
1NCI）の「了解覚書」（英文併記、
JBA日本語訳）
を付けることとした。

平成 25 年 3 月1 日
一般財団法人 バイオインダストリー協会“MEMORANDUM OF UNDERSTANDING between [Source Country Organization] and THE DEVELOPMENTAL THERAPEUTICS PROGRAM DIVISION OF CANCER TREATMENT AND DIAGNOSISNATIONAL CANCER INSTITUTE”
出典：“Contracting for ABS : the legal and scientific implications of bioprospecting contracts” のAppendix E(pp257-260)、IUCN Environmental Policy and Law Paper No. 67/4, 2009（http://www.iucn.org/about/work/programmes/environmental_law/elp_resources/elp_res_publications/?
uPubsID=3904）（2013年1月25日アクセス）1☨࿖࿖┙≸⎇ⓥᚲߩੌ⸃ⷡᦠMEMORANDUM OF UNDERSTANDING

⾗Ḯឭଏ࿖䈱⚵❱䋨SCO䋩䈫

between [Source Country Organization] and THE☨࿖࿖┙≸⎇ⓥᚲ≸ᴦ≮䊶⸻ᢿㇱ㐷ഃ⮎

DEVELOPMENTAL THERAPEUTICS

䊒䊨䉫䊤䊛䈫䈱ੌ⸃ⷡᦠPROGRAM DIVISION OF CANCER
TREATMENT AND DIAGNOSIS NATIONALCANCER INSTITUTEThe Developmental Therapeutics Program (DTP),☨࿖࿖┙≸⎇ⓥᚲ㧔NCI㧕≸ᴦ≮࡮⸻ᢿㇱ㐷

Division of Cancer Treatment and Diagnosis

㧔DCTD㧕ഃ⮎ࡊࡠࠣ࡜ࡓ㧔DTP㧕ߪ‫⃻ޔ‬(DCTD), National Cancer Institute (NCI) is࿷‫ޔ‬ᣂߚߥ᛫ࠟࡦ೷ࠍ⷗޿ߛߔߴߊ‫ޔ‬วᚑൻ

currently screening synthetic compounds andว‛ਗ߮ߦᬀ‛‫ޔ‬ᶏᵗࡑࠢࡠ↢‛෸߮ᶏᵗᓸ

natural product materials derived from plants,↢‛ߦ↱᧪ߔࠆᄤὼ‛᧚ᢱߩࠬࠢ࡝࡯࠾ࡦ

marine macro-organisms and micro-organisms asࠣࠍⴕߞߡ޿ࠆ‫ޕ‬DTP ߪ NCI ߩഃ⮎ߩߚ߼

potential sources of novel anticancer drugs. The

ߩࡊࡠࠣ࡜ࡓߢ޽ࠅ‫ޔ‬NCI ߪ☨࿖᡽ᐭߩ଻

DTP is the drug discovery program of the NCIஜ␠ળ⑔␩⋭㧔DHHS㧕ߦᚲዻߔࠆ࿖┙ⴡwhich is an Institute of the National Institutes of↢⎇ⓥᚲ㧔NIH㧕ߩ৻ᯏ㑐ߢ޽ࠆ‫ޕ‬NCI ߪ‫ޔ‬

Health (NIH), an arm of the Department of Healthഃ⮎㐿⊒ߦ߅ߌࠆᄤὼ‛ߩน⢻ᕈࠍតࠆ৻

and Human Services (DHHS) of the United Statesᣇߢ‫‛↢ޔ‬ᄙ᭽ᕈߩ଻ో෸߮ᜬ⛯น⢻ߥ೑↪

Government. While investigating the potential ofࠍផㅴߔࠆߎߣࠍᦸࠎߢ߅ࠅ‫⾗ޔ‬Ḯឭଏ࿖ౝnatural products in drug discovery andߦ߅޿ߡណ㓸ߐࠇߚ↢‛߆ࠄ㐿⊒ߒߚක⮎development, NCI wishes to promote theຠߩ໡ᬺൻߦ㓙ߒߡߪ‫ޔ‬ᒰ⹥⾗Ḯឭଏ࿖ߩ⚵conservation and sustainable utility of biological❱෸߮࿖᳃ߦኻߒ⵬ఘࠍⴕ߁ᔅⷐᕈࠍ⹺⼂diversity, and recognizes the need to compensateߒߡ޿ࠆ‫ޕ‬source country organizations and peoples in theevent of commercialization of a drug developed
from an organism collected within their countries’
borders.
DTP/NCI has an interest in investigating plants,

DTP/NCI ߪ‫ޔ‬㨇⾗Ḯឭଏ࿖㨉ߩᬀ‛‫ޔ‬㒽਄

terrestrial and marine micro-organisms andᓸ↢‛‫ޔ‬ᶏᵗᓸ↢‛෸߮ᶏᵗࡑࠢࡠ↢‛ߩ⺞marine macro-organisms from [Source Country]ᩏߦ㑐ᔃࠍ᦭ߒߡ߅ࠅ‫⺞ߩߎޔ‬ᩏߦ߅޿ߡ

and wishes to collaborate with the [Source Country㨇⾗Ḯឭଏ࿖ߩ⚵❱㧔એਅ‫ޟ‬SCO‫߁޿ߣޠ‬㧕㨉

Organization, SCO] in this investigation. DTP/NCI

ߣද௛ߔࠆߎߣࠍᦸࠎߢ޿ࠆ‫ޕ‬
DTP/NCI ߪ‫ޔ‬will make sincere efforts to transfer knowledge,․⸵ᛛⴚߦ㑐ㅪߔࠆ⍮⊛⽷↥ߩ଻⼔ߦ㑐ߒexpertise, and technology related to drug discoveryߡ⋧੕ߦฃߌ౉ࠇน⢻ߥ଻⸽߇޽ࠆߎߣࠍ

and development to [SCO] in [Source Country, SC]᧦ઙߣߒߡ‫ޔ‬ഃ⮎㐿⊒ߦ㑐ㅪߔࠆ⍮⼂‫ޔ‬ኾ㐷

(as the agent appointed by the [Source Country]⍮⼂෸߮ᛛⴚࠍ
㨇⾗Ḯឭଏ࿖
㧔SC㧕
㨉
ߩ
㨇SCO㨉

Government), subject to the provision of mutually㧔㨇⾗Ḯឭଏ࿖㨉ߩ᡽ᐭߦࠃࠅછ๮ߐࠇߚઍ

acceptable guarantees for the protection ofℂੱߣߒߡ㧕ߦ⒖ォߔࠆࠃ߁⺈ታߦദജߔࠆ



intellectual property associated with any patented߽ߩߣߔࠆ‫৻ޕ‬ᣇ㨇SCO㨉ߪ‫ޔ‬㨇⾗Ḯឭଏ࿖㨉technology. [SCO], in turn, desires to collaborateߩᬀ‛‫ޔ‬㒽਄ᓸ↢‛‫ޔ‬ᶏᵗᓸ↢‛‫ޔ‬ᶏᵗࡑࠢclosely with the DTP/NCI in pursuit of theࡠ↢‛෸߮วᚑൻว‛ߩ⺞ᩏࠍㅴ߼ࠆߦᒰ

investigation of [Source Country]’s plants,ߚࠅ‫ᦠⷡ⸃ੌᧄޔ‬㧔MOU㧕ߩએਅߩ᧦ઙ෸

terrestrial and marine micro-organisms and߮ⷙቯߦᓥ޿‫ޔ‬DTP/NCI ߣ✕ኒߦද௛ߔࠆ

marine macro-organisms and selected syntheticߎߣࠍᦸࠎߢ޿ࠆ‫ޕ‬
㨇SCO㨉ߪㆡቱ‫ޔ‬㒽਄ᬀ

compounds subject to the following conditions and‛‫ޔ‬ᶏᵗࡑࠢࡠ↢‛෶ߪᶏᵗᓸ↢‛ߩណ㓸෸

stipulations of this Memorandum of߮ടᎿࠍⴕ߁߽ߩߣߔࠆ‫ޕ‬ណ㓸ߩታᣉߦᒰߚ

Understanding (MOU). [SCO] will perform theߞߡߪ‫⾗ޔ‬Ḯឭଏ࿖ߩߔߴߡߩࠕࠢ࠮ࠬ᡽╷collection and processing of terrestrial plants,෸߮੐೨ߩᖱႎߦၮߠߊหᗧߩⷐઙߩㆩ቞

marine macro-organisms or micro-organisms asߦߟ޿ߡ‫ޔ‬㨇SCO㨉߇න⁛ߢ⽿છࠍ⽶߁ߎߣ

appropriate. It is understood that the [SCO] will߇ੌ⸃ߐࠇߡ޿ࠆ‫ޕ‬NCI ߪ‫ߥ߁ࠃߩߎޔ‬᡽

be solely responsible for abiding by all source╷ߦኻߔࠆ㨇SCO㨉ߩ޿߆ߥࠆ㆑෻ߦ߽⽿

country’s access policies and requirements for priorછࠍ⽶ࠊߥ޿‫ޕ‬

informed consent in the performance of collections.
The NCI bears no responsibility for any
contravention of such policies by the [SCO].
1) On the basis of in-house screening results in its

1) 㨇SCO㨉ߪ‫ޔ‬DTP/NCI ߢߩ᛫ࠟࡦ⹜㛎

anticancer screens, [SCO] may select bothߦଏߔࠆߚ߼‫ߩ❱⚵⥄ޔ‬᛫ࠟࡦࠬࠢ࡝࡯

synthetic compounds and extracts of plants,ࡦߦࠃࠆ⥄⚵❱ౝߢߩࠬࠢ࡝࡯࠾ࡦࠣ⚿marine macro-organisms and micro-organismsᨐߦၮߠ߈‫ޔ‬วᚑൻว‛ਗ߮ߦᬀ‛‫ޔ‬ᶏ(subject to previously determined limits as toᵗࡑࠢࡠ↢‛෸߮ᶏᵗᓸ↢‛ߩ᛽಴‛ߩ

numbers per year) for anticancer testing atਔᣇࠍㆬᛯߔࠆߎߣ߇ߢ߈ࠆ㧔੍߼᳿߼

DTP/NCI. If suitable in-house screens are notࠄࠇߚᐕ㑆૶↪ᢙ೙㒢ߦᓥ߁㧕
‫ޕ‬
㨇SCO㨉

available at [SCO], a list of available materialsߦ߅޿ߡㆡಾߥ⚵❱ౝࠬࠢ࡝࡯ࡦ߇ᓧࠄ

may be sent to DTP/NCI.

ࠇߥ޿႐ว‫౉ޔ‬ᚻߢ߈ࠆ᧚ᢱߩ࡝ࠬ࠻ࠍ
DTP/NCI ߳ㅍઃߔࠆߎߣ߇ߢ߈ࠆ‫ޕ‬2) Prior to submission of the materials, [SCO] will2) ᧚ ᢱ ߩ ឭ ಴ ߦ వ ┙ ߜ ‫ޔ‬㨇 SCO 㨉 ߪ ‫ޔ‬send a data sheet, to be held in confidence by

DTP/NCI ߇ㆊ෰ߩឭ಴⸥㍳ߩ࠺࡯࠲ࡌ

DTP/NCI, on each material so that DTP/NCI

࡯ࠬߣᾖวߢ߈ࠆࠃ߁ߦ‫ޔ‬୘‫᧚ߩޘ‬ᢱߦ

may check its databases for records of prior㑐ߔࠆ࠺࡯࠲ࠪ࡯࠻ࠍㅍઃߔࠆ߽ߩߣ

submission to DTP/NCI.

ߒ‫ޔ‬DTP/NCI ߪߎࠇࠍ⒁ኒᛒ޿ߣߔࠆ‫ޕ‬3) For pure compounds, the data sheet(s) will give3) ⚐☴ൻว‛ߦߟ޿ߡߪ‫ߦ࠻࡯ࠪ࠲࡯࠺ޔ‬pertinent available data as to chemicalߪ‫ޔ‬ൻቇ⚵ᚑ‫ޔ‬᭴ㅧ‫❱⚵ޔ‬ౝߢߩࠬࠢ࡝

constitution, structure, available biological data࡯࠾ࡦࠣߩ⚿ᨐ╬ߩ౉ᚻߢ߈ࠆ↢‛ቇ⊛

including in-house screening results, solubility,࠺࡯࠲‫ޔ‬ṁ⸃ᕈ‫ޔ‬Ქᕈ‫ޔ‬ਗ߮ߦขࠅᛒ޿‫ޔ‬

toxicity and any precautions which need to be଻▤෸߮ャㅍߩ㓙ߦ቞ࠆߴ߈ᵈᗧ੐㗄ߦfollowed in handling, storage and shipping.

ߟ޿ߡ‫౉ޔ‬ᚻߢ߈ࠆ㑐ㅪ࠺࡯࠲ࠍ⸥タߔ

ࠆ߽ߩߣߔࠆ‫ޕ‬For crude extracts, data will be provided as to☻᛽಴‛ߦߟ޿ߡߪ‫ޔ‬᛽಴Ḯߢ޽ࠆ↢‛the source organism taxonomy, location andߩಽ㘃‫ޔ‬ណ㓸࿾‫ޔ‬ណ㓸ᣣ‫ޔ‬ᒰ⹥↢‛ߦ㑐

date of collection, any hazards associated withㅪߔࠆෂ㒾‫౉ޔ‬ᚻߢ߈ࠆ↢‛ቇ⊛࠺࡯࠲the organism, available biological data and any෸߮ᒰ⹥↢‛෶ߪ᛽಴‛ߩᣢ⍮ߩක≮↪

known medicinal uses of the organism/extracts.

ㅜ߇޽ࠇ߫ߘߩ↪ㅜߦߟ޿ߡ‫ࠍ࠲࡯࠺ޔ‬⸥タߔࠆ߽ߩߣߔࠆ‫ޕ‬4) DTP will inform [SCO] which of the materials4) DTP ߪߤߩ᧚ᢱ߇ DTP ߦߣߞߡᣂⷙߢ

are new to the program, and such materials will޽ࠆ߆ࠍ㨇SCO㨉ߦႎ๔ߔࠆ߽ߩߣߒ‫ޔ‬be shipped to DTP for screening. DTP willᒰ⹥᧚ᢱ߇ࠬࠢ࡝࡯࠾ࡦࠣߩߚ߼ߦ

provide a record of the accession number for the

DTP ߦャㅍߐࠇࠆ߽ߩߣߔࠆ‫ޕ‬DTP ߪ

materials. Quantities of materials required forᒰ⹥᧚ᢱߩࠕࠢ࠮࠶࡚ࠪࡦ⇟ภࠍ⸥㍳ߔ

initial testing are 5 mg for pure compounds andࠆ߽ߩߣߔࠆ‫ޕ‬ೋᦼ⹜㛎ߦᔅⷐߥ᧚ᢱߩ

10 mg for crude extracts.

㊂ߪ‫☴⚐ޔ‬ൻว‛ߦߟ޿ߡߪ 5mg‫☻ޔ‬᛽಴‛ߦߟ޿ߡߪ 10mg ߢ޽ࠆ‫ޕ‬5) a) Data provided by [SCO] will be considered as

5)a) DTP/NCI ߪ‫ޔ‬
㨇SCO㨉߇ឭଏߔࠆ࠺
࡯࠲ߦߘߩᣦߩ⴫␜߇޽ࠇ߫‫ࠇߘޔ‬

confidential information of [SCO], if solabeled, and will be held confidentially byࠍ㨇SCO㨉ߩ⒁ኒᖱႎߣ⷗ߥߒߡ⒁DTP/NCI, unless the data are otherwiseኒᛒ޿ߣߔࠆ߇‫ޔߒߛߚޔ‬ᒰ⹥࠺࡯available from public sources. No࠲߇౏㐿ߐࠇߡ޿ࠆ࠰࡯ࠬ߆ࠄ౉ᚻ

confidential information of [SCO] will be keptߢ߈ࠆ႐วߦߪ‫ߩߎޔ‬㒢ࠅߢߪߥ޿‫ޕ‬in files open to the public either by DTP/NCI,

DTP/NCI‫⹜ޔ‬㛎ᬌᩏᯏ㑐෶ߪ࠺࡯࠲

testing laboratories, or data processing

ಣℂᯏ㑐ߥߤ☨࿖᡽ᐭߩᆔ⸤ᬺോࠍ

facilities, all of which are U.S. governmentⴕ߁⠪ߪ޿ߕࠇ߽‫ޔ‬
㨇SCO㨉ߩ৻ಾߩ

contractors. Only those employees directly⒁ኒᖱႎࠍ౏㐿ࡈࠔࠗ࡞ߦ଻▤ߒߥ

engaged in the operation of DTP/NCI will޿߽ߩߣߔࠆ‫ޕ‬DTP/NCI ߩᬺോߦ⋥have access to the files of informationធ៤ࠊࠆ⡯ຬߩߺ߇‫⒁ޔ‬ኒߩ᧚ᢱߩ

regarding the source and nature of಴ᚲ෸߮ᕈ⾰ߦ㑐ߔࠆᖱႎࡈࠔࠗ࡞

confidential materials, unless the release ofߦࠕࠢ࠮ࠬߢ߈ࠆ߽ߩߣߔࠆ߇‫ߚޔ‬data about the materials is required underߛߒ‫ޔ‬ᒰ⹥᧚ᢱߦ㑐ߔࠆ࠺࡯࠲ߩ౏

law or by court order. In the event of⴫߇ᴺᓞߦၮߠ߈෶ߪⵙ್ᚲߩ๮઎

expiration of this agreement, theߦࠃߞߡⷐ᳞ߐࠇࠆ႐วߦߪ‫ߩߎޔ‬

confidentiality of data provided by the [SCO]㒢ࠅߢߪߥ޿‫ᦼߩᦠⷡ⸃ੌᧄޕ‬㒢߇will be maintained.

ḩੌߒߚ႐วߢ߽‫ޔ‬
㨇SCO㨉߇ឭଏߒ
ߚ࠺࡯࠲ߩ⒁ኒᕈߪ଻ᜬߔࠆ߽ߩߣߔࠆ‫ޕ‬b) All test results will be provided to [SCO] assoon as they are available, but not later thanb) ⹜㛎ߩ⚿ᨐߪߔߴߡ‫ޔ‬ᓧࠄࠇᰴ╙ߚ
ߛߜߦ㨇SCO㨉ߦឭଏߔࠆ߽ߩߣߔ

270 days (nine months) from the date ofࠆ߇‫⹜ޔ‬ᢱฃ㗔ߩᣣ߆ࠄ 270 ᣣ㧔9receipt of the sample. If available, in vitroࠞ᦬㧕ࠍᦼ㒢ߣߔࠆ‫⹜ࡠ࠻ࡆࡦࠗޕ‬test results will be delivered within 90 days㛎ߩ⚿ᨐߪ‫ޔ‬น⢻ߢ޽ࠇ߫‫⹜ޔ‬ᢱฃfrom receipt of the sample. [SCO] will be㗔ߩᣣ߆ࠄ 90 ᣣએౝߦឭଏߔࠆ߽

informed in writing of any delays beyond thisߩߣߔࠆ‫ᦼߩߎޕ‬㒢㧔270 ᣣ㧕ࠍ⿥

period (270 days) together with an߃ࠆ޿߆ߥࠆㆃᑧߦߟ޿ߡ߽‫ߩߘޔ‬

explanation of the reason(s) for delay.

ᣦࠍㆃᑧℂ↱䈫䈫䉅䈮ᦠ㕙䈪䌛SCO㨉䈮ႎ๔䈜䉎䉅䈱䈫䈜䉎䇯㩷c) Unless the release of test results is requiredc) ᴺᓞߦၮߠ߈෶ߪⵙ್ᚲߩ๮઎ߦࠃ

under law or by court order, the parties willߞߡ⹜㛎⚿ᨐߩ౏⴫߇ⷐ᳞ߐࠇࠆ႐

keep the test results andวࠍ㒰߈‫ޔ‬ਔᒰ੐⠪ߪ‫⹜ޔ‬㛎⚿ᨐ෸subsequently-developed data confidential߮ߘߩᓟ૞ᚑߐࠇߚ࠺࡯࠲ࠍ‫ ╙ޔ‬15

until published in accordance with Article 15᧦ߩⷙቯߦᓥߞߡ౏⴫ߔࠆ߹ߢ‫ޔ‬෶

or until corresponding patent applications areߪ╙ 9 ᧦ߦᓥߞߡ㑐ଥ․⸵ࠍ಴㗿ߔ

filed in accordance with Article 9.

ࠆ߹ߢ‫⒁ޔ‬ኒߣߔࠆ߽ߩߣߔࠆ‫ޕ‬6) Any extracts exhibiting significant activity will6) 㗼⪺ߥᵴᕈࠍ␜ߔ᛽಴‛ߦߟ޿ߡߪ‫⹺ޔ‬

be further studied by bioassay-guided߼ࠄࠇߚᵴᕈߦ㑐ਈߔࠆ⚐☴ൻว‛ࠍ

fractionation in order to isolate the pureන㔌ߔࠆߚ߼‫ࠗ࠮࠶ࠕࠝࠗࡃޔ‬ᜰᮡಽ↹

compound(s) responsible for the observedߦࠃࠅߐࠄߦ⎇ⓥߔࠆ߽ߩߣߔࠆ‫ޕ‬ᒰ⹥

activity. Such fractionation will be carried outಽ↹ߪ㨇SCO㨉ߩ⎇ⓥᣉ⸳ߢⴕ߁߽ߩ

in [SCO] laboratories. If [SCO] has noߣߔࠆ‫ޕ‬
㨇SCO㨉߇ࡃࠗࠝࠕ࠶࠮ࠗࠍ೑

available bioassay, DTP/NCI may assist [SCO]↪ߔࠆߎߣ߇ߢ߈ߥ޿႐ว‫ޔ‬DTP/NCI

to establish the necessary bioassay systemsߪ‫ޔ‬ᔅⷐߥ⾗Ḯ߇ᓧࠄࠇࠆߥࠄ߫‫ޔ‬

subject to the availability of the necessary㨇SCO㨉߇ᔅⷐߥࡃࠗࠝࠕ࠶࠮ࠗ♽ࠍ

resources. Alternatively, or in addition,᭴▽ߔࠆߩࠍᡰេߔࠆߎߣ߇ߢ߈ࠆ‫ޕ‬೎

suitably qualified designated [SCO] scientists

ߩᣇᴺߣߒߡߪ‫ޔ‬෶ߪߎࠇߦട߃ߡ‫ޔ‬ਅ

may be sent to DTP/NCI for the isolation

⸥╙ 7 ᧦ߦⷙቯߔࠆ᧦ઙߦᓥ޿‫ޔ‬ㆡಾߥ

studies subject to the terms stated below in⾗ᩰࠍᜬߟ㨇SCO㨉ߩ⑼ቇ⠪ߢᜰฬߐ

Article 7. In addition, DTP/NCI may assist theࠇߚ⠪ࠍ‫ޔ‬න㔌⎇ⓥߩߚ߼ߦ DTP/NCI[SCO], thereby assisting the [Source Country],ߦᵷ㆜ߔࠆߎߣ߇ߢ߈ࠆ‫ߦࠄߐޕ‬to develop the capacity to undertake drug

DTP/NCI ߪ‫ޔ‬㒽਄↢‛෸߮ᶏᵗ↢‛߆

discovery and development, includingࠄߩᵴᕈൻว‛ߩࠬࠢ࡝࡯࠾ࡦࠣ෸߮

capabilities for the screening and isolation ofන㔌ߩ⢻ജࠍ฽߼‫ޔ‬ഃ⮎㐿⊒ࠍⴕ߁⢻ജ

active compounds from terrestrial and marineߩ㐿⊒㕙ߢ㨇SCO㨉ࠍᡰេߒ‫ߦࠇߘޔ‬organisms.

ࠃࠅ㨇⾗Ḯឭଏ࿖㨉ࠍᡰេߔࠆߎߣ߇ߢ
߈ࠆ‫ޕ‬7) Subject to the provision that suitable laboratory7) ㆡಾߥ⎇ⓥᣉ⸳ߣߘߩઁᔅⷐߥ߽ߩ߇
ᓧࠄࠇࠆߎߣࠍ᧦ઙߣߒߡ‫ޔ‬DTP/NCI

space and other necessary resources are

available, DTP/NCI agrees to consider invitingߪ‫⎇ߩߘޔ‬ⓥᣉ⸳ߦ߅޿ߡ‫ޔ‬෶ߪਔᒰ੐

senior technician(s) and/or scientist(s)⠪߇หᗧߔࠆ႐วߦߪ‫ߦᦠⷡ⸃ੌᧄޔ‬ၮ

designated by [SCO] to work in the laboratoriesߠߊ૞ᬺࠍㅴ߼ࠆ਄ߢ᦭↪ߣᕁࠊࠇࠆ

of DTP/NCI or, if the parties agree, inᛛⴚࠍណ↪ߒߡ޿ࠆ⎇ⓥᣉ⸳ߦ߅޿ߡ

laboratories using technology which would be૞ᬺࠍⴕ߁ߚ߼‫ޔ‬
㨇SCO㨉ߩᜰฬߔࠆ਄

useful in furthering work under this MOU.

Ꮸߩᛛⴚ⠪෸߮/෶ߪ⑼ቇ⠪ߩ᜗⡜ࠍᬌThe duration of such visits would not exceed⸛ߔࠆߎߣߦหᗧߔࠆ‫ߩߘޕ‬ṛ࿷ᦼ㑆

one year except by prior agreement betweenߪ‫ޔ‬㨇SCO㨉ߣ DTP/NCI ߇੐೨ߦวᗧ

[SCO] and DTP/NCI. The designated visitingߔࠆ႐วࠍ㒰߈‫ޔ‬1 ᐕࠍ⿥߃ߥ޿߽ߩߣ

scientist(s) will be subject to provisions usuallyߔࠆ‫ޕ‬ᜰฬߐࠇߚ᜗⡜⑼ቇ⠪ߪ‫ޔ‬࿖┙ⴡgoverning Guest Researchers at NIH.

↢⎇ⓥᚲ㧔NIH㧕ߩቴຬ⎇ⓥຬߦㅢᏱㆡ

Cost-sharing and other conditions of visits will↪ߐࠇࠆ⻉ⷙቯߦᓥ߁߽ߩߣߔࠆ‫ޕ‬ṛ࿷

be negotiated in good faith prior to the arrival ofߩ⾌↪ಽᜂߘߩઁߩ᧦ઙߦߟ޿ߡߪ‫ޔ‬᜗

the visiting scientist(s).

⡜⑼ቇ⠪ߩ೔⌕೨ߦ⺈ታߦද⼏ߔࠆ߽ߩߣߔࠆ‫ޕ‬8) In the event that an agent isolated and purified

8) 㨇SCO㨉߇ឭଏߒߚ᧚ᢱ߆ࠄන㔌෸߮from materials provided by [SCO], and/or a♖⵾ߐࠇߚ‛⾰෸߮/෶ߪ㨇SCO㨉߇ឭsynthetic compound provided by [SCO] meetsଏߒߚวᚑൻว‛߇‫ޔ‬NCI ߩ≸ᴦ≮࡮

the criteria established by the Drug⸻ᢿㇱ㐷㧔DCTD㧦DTP ߩ਄ㇱ⚵❱㧕

Development Group (DDG) of NCI’s DCTDߩ ⮎ ೷ 㐿 ⊒ ࠣ ࡞ ࡯ ࡊ 㧔 Drug

(DTP’s parent organization), which would

Development Group‫ޔ‬એਅ‫ޟ‬DDG‫ߣޠ‬

include, but not be limited to, in vivo activity in޿߁㧕߇╷ቯߒߚၮḰ㧔ߍߞᱤ㘃ࡕ࠺࡞rodent models, further development of theߦ߅ߌࠆ↢૕ౝᵴᕈࠍ฽߻߇ߎࠇߦ㒢agent may be undertaken by DTP/NCI inࠄߥ޿㧕ࠍḩߚߔ႐วߦߪ‫ޔ‬DTP/NCI

agreement with the [SCO]. Further

ߪ㨇SCO㨉ߣวᗧߩ਄ߢ‫ޔ‬ᒰ⹥‛⾰ߦ

development of the specific agent may includeߟ޿ߡߐࠄߥࠆ㐿⊒ࠍㅴ߼ࠆߎߣ߇ߢ

but not be limited to analog development߈ࠆ‫ޕ‬ᒰ⹥‛⾰ߩߐࠄߥࠆ㐿⊒ߦߪ‫ޔ‬කthrough medicinal and/or combinatorial⮎ຠൻቇ‫࡝࠻ࠬࡒࠤ࡞ࠕ࡝࠻࠽ࡆࡦࠦޔ‬chemistry, formulation, pharmacology and/or࡯‫⵾ޔ‬೷⎇ⓥ‫⮎ޔ‬ℂቇ⎇ⓥ෸߮/෶ߪᲥ

toxicology studies. Once an active agent isᕈ⎇ⓥߦࠃࠆࠕ࠽ࡠࠣ㐿⊒ࠍ฽߻ߎߣ

approved by DTP/NCI for preclinical߇ߢ߈ࠆ߇‫ߦࠇߎޔ‬㒢ࠄߥ޿‫ޕ‬DTP/NCI

development (i.e., has passed the DDG at Stage߇ᵴᕈ‛⾰ߩ೨⥃ᐥ㐿⊒ࠍᛚ⹺ߒߚ႐IIA), DTP/NCI may collaborate with [SCO]ว㧔ߔߥࠊߜ DDG ߩࠬ࠹࡯ࠫ IIA ࠍㅢ

scientists in the development of the specificㆊߒߚ႐ว㧕‫ޔ‬DTP/NCI ߪߘߩ‛⾰ߩ㐿

agent.

⊒㕙ߢ㨇SCO㨉ߩ⑼ቇ⠪ߣද௛ߔࠆߎ
ߣ߇ߢ߈ࠆ‫ޕ‬9) 㨇SCO㨉෸߮ DTP/NCI ߪߣ߽ߦ‫ࡦࠗޔ‬9) Both [SCO] and DTP/NCI recognize thatinventorship will be determined under patentࡌࡦ࠲࡯ࠪ࠶ࡊ߇․⸵ᴺߦၮߠ޿ߡ᳿

law. DTP/NCI/NIH and [SCO] will, asቯߐࠇࠆߎߣࠍ⹺߼ࠆ‫ߦᦠⷡ⸃ੌᧄޕ‬ၮ

appropriate, jointly seek patent protection onߠ޿ߡ DTP/NCI ෸߮㨇SCO㨉ߩ⡯ຬ߇

all inventions developed jointly under this౒หߢ㐿⊒ߒߚ⊒᣿ߦߟ޿ߡߪߔߴߡ‫ޔ‬

MOU by DTP/NCI and [SCO] employees, and

DTP/NCI/NIH ෸߮㨇SCO㨉߇ㆡቱ‫౒ޔ‬will seek appropriate protection abroad,หߢ․⸵ᮭ଻⼔ࠍ᳞߼ࠆ߽ߩߣߒ‫߹ޔ‬

including in [Source Country], if appropriate.

ߚ‫ޔ‬ㆡᒰߥ႐วߦߪ‫ޔ‬㨇⾗Ḯឭଏ࿖㨉ߩ

Application for patent protection on inventions࿖ౝࠍ฽߼‫ઁޔ‬࿖ߦ߅ߌࠆㆡಾߥ଻⼔ࠍmade by [SCO] employees alone will be the᳞߼ࠆ߽ߩߣߔࠆ‫ޕ‬
㨇SCO㨉ߩ⡯ຬߩߺ

responsibility of [SCO]. Application for patentߢ㐿⊒ߒߚ⊒᣿ߦኻߔࠆ․⸵ᮭ଻⼔ߩ

protection on inventions made by DTP/NCI಴㗿ߪ‫ޔ‬
㨇SCO㨉ߩ⽿છߣߔࠆ‫ޕ‬DTP/NCI

employees alone will be the responsibility ofߩ⡯ຬߩߺߢ㐿⊒ߒߚ⊒᣿ߦኻߔࠆ․DTP/NCI.

⸵ᮭ଻⼔ߩ಴㗿ߪ‫ޔ‬DTP/NCI ߩ⽿છߣߔࠆ‫ޕ‬With respect only to those compounds that have

DCTD ߦࠃࠅᴦ㛎߇⸘↹ߐࠇࠆࠃ߁ߥ

been determined to possess such significant㗼⪺ߥ᛫ࠟࡦ૞↪߇⷗ㄟ߹ࠇࠆߣ್ᢿ

anti-cancer potential as to be scheduled forߐࠇߚൻว‛ߦ㑐ߒߡߩߺ‫☨ޔ‬࿖᡽ᐭ

clinical trials by DCTD, the U.S. Governmentߪ‫ޔ‬㨇SCO㨉߇ᒰ⹥ൻว‛ߦ㑐ߒ෶ߪᒰ

shall have a royalty-free, irrevocable,⹥ൻว‛ߩ೑↪ᣇᴺߦ㑐ߒߡᚲ᦭෶ߪ

nonexclusive license to manufacture and/or use

ขᓧߔࠆ․⸵ߩ⺧᳞ߩ▸࿐ߦ⸥タߐࠇby or for the U.S. Government the invention(s)ߡ޿ࠆ⊒᣿ߦߟ޿ߡ‫☨ޔ‬࿖᡽ᐭ⥄り߇෶

claimed in any patents that [SCO] may have orߪ☨࿖᡽ᐭߩߚ߼ߦߎࠇࠍ⵾ㅧ෸߮/෶

may obtain on such compounds or on a processߪ೑↪ߔࠆ‫࡯ࠖ࠹࡝ࡗࠗࡠޔ‬ήᢱߢขᶖ

for use of such compounds. However, thisਇ⢻߆ߟ㕖⁛භ⊛ߥ࡜ࠗ࠮ࡦࠬࠍ᦭ߔ

license will apply only to [SCO] patents thatࠆ߽ߩߣߔࠆ‫ࠬࡦ࠮ࠗ࡜ߩߎߒߛߚޕ‬rely upon data generated by DTP/NCI orߪ‫ޔ‬DTP/NCI ෶ߪ DTP/NCI ߩ⹜㛎ᬌ

DTP/NCI testing laboratories. This licenseᩏᯏ㑐߇૞ᚑߒߚ࠺࡯࠲ߦଐሽߔࠆ

shall be only for medical research purposes

㨇SCO㨉ߩ․⸵ߦߩߺㆡ↪ߐࠇࠆ߽ߩ

related to or connected with the therapy ofߣߔࠆ‫ࡦࠟޔߪࠬࡦ࠮ࠗ࡜ߩߎޕ‬ᴦ≮ߦcancer. The term “medical research purposes”㑐ଥ෶ߪ㑐ㅪߔࠆකቇ⊛ߥ⎇ⓥ⋡⊛ߩ

as used herein shall not include treatment ofߺࠍኻ⽎ߣߔࠆ߽ߩߣߔࠆ‫ߌ߅ߦ᧦ᧄޕ‬patients outside of clinical trials or commercialࠆ‫ޟ‬කቇ⊛ߥ⎇ⓥ⋡⊛‫ޔߪߦޠ‬ᴦ㛎એᄖ

distribution of the compounds.

ߢߩᖚ⠪ߩᴦ≮෶ߪൻว‛ߩ⽼ᄁࠍ฽߹ߥ޿߽ߩߣߔࠆ‫ޕ‬10)DTP/NCI will make a sincere effort to transfer

10) DTP/NCI ߪ‫⸵․ޔ‬ᛛⴚߦ㑐ㅪߔࠆ⍮⊛any knowledge, expertise, and technology

⽷↥ߩ଻⼔ߦ㑐ߒߡ⋧੕ߦฃߌ౉ࠇน

developed during such collaboration in the⢻ߥ଻⸽߇޽ࠆߎߣࠍ᧦ઙߣߒߡ‫ޔ‬ഃ⮎discovery and development process to [SCO],㐿⊒ࡊࡠ࠮ࠬߢද௛ߔࠆ㑆ߦ↢ߺ಴ߐ

subject to the provision of mutually acceptableࠇߚ⍮⼂‫ޔ‬ኾ㐷⍮⼂෸߮ᛛⴚࠍ㨇SCO㨉

guarantees for the protection of intellectual

ߦ⒖ォߔࠆࠃ߁⺈ታߦദജߔࠆ߽ߩߣ

property associated with any patentedߔࠆ‫ޕ‬

technology.

11) All licenses granted on any patents arising from11) ᧄੌ⸃ⷡᦠߩ⻉᧦ઙߦၮߠ޿ߡⴕ߁ද

the collaboration conducted under the terms of௛߆ࠄ↢ߓࠆ․⸵ߦ㑐ߒߡઃਈߐࠇࠆ

this MOU shall contain a clause referring toߔߴߡߩ࡜ࠗ࠮ࡦࠬߦߪ‫ߦᦠⷡ⸃ੌᧄޔ‬this MOU and shall indicate that the licensee⸒෸ߔࠆ᧦㗄ࠍ฽߻߽ߩߣߒ‫ࡦ࠮ࠗ࡜ޔ‬has been apprised of this MOU.

ࠪ࡯߇ᧄੌ⸃ⷡᦠߦߟ޿ߡᛚ⍮ߒߡ޿ࠆᣦࠍ⸥タߔࠆ߽ߩߣߔࠆ‫ޕ‬12) ߎߩද௛ߩਅߢ⊒⷗ߐࠇߚ‛⾰ߦኻߔ12) Should an NCI/NIH patent on an agent
discovered under this collaboration eventually

ࠆ NCI/NIH ߩ․⸵ߦߟ޿ߡ‫⮎⵾ޔ‬ડᬺ

be licensed to a pharmaceutical company forߦ⵾ㅧ⽼ᄁߩ࡜ࠗ࠮ࡦࠬࠍਈ߃ࠆ႐ว‫ޔ‬

production and marketing, DTP/NCI will

DTP/NCI ߪ‫ޔ‬NIH/OTT㧔ᛛⴚ⒖ォዪ㧕

request that NIH/OTT require the licensee to߇࡜ࠗ࠮ࡦࠪ࡯ߦኻߒ‫ޔ‬ᒰ⹥࡜ࠗ࠮ࡦࠬ

negotiate and enter into agreement(s) withߩ✦⚿߆ࠄ 12 ࠞ᦬એౝߦ㨇SCO㨉෸߮[SCO] and/or an appropriate [Source Country]/෶ߪㆡᒰߥ㨇⾗Ḯឭଏ࿖㨉ߩ᡽ᐭᯏ㑐

Government agency(ies) within twelve (12)ߣ੤ᷤߒߡදቯࠍ⚿߱ࠃ߁⟵ോઃߌࠆ

months from the execution of said license. Theߎߣࠍ‫ޕࠆߔߣߩ߽ࠆߔ⺧ⷐޔ‬ᒰ⹥දቯ

agreement(s) will address the concern on theߢߪ‫ޔ‬㑐ㅪߔࠆᯏ㑐‫⎇ޔ‬ⓥᚲ෸߮/෶ߪ

part of the [Source Country] government that୘ੱ߇ࡠࠗࡗ࡝࠹ࠖ࡯෸߮ઁߩᒻᘒߩ

pertinent agencies, institutions and/or persons⵬ఘࠍㆡቱฃߌขࠆߣ޿߁‫ޔ‬㨇⾗Ḯឭଏ

receive royalties and other forms of࿖㨉ߩ᡽ᐭߩ㑐ᔃ੐ߦኻಣߔࠆ߽ߩߣߔ

compensation, as appropriate.

ࠆ‫ޕ‬Such terms will apply equally to inventions਄⸥ߩ᧦ઙߪ‫ޔ‬ᄤὼ‛᧚ᢱ߆ࠄߩ⋥ធߩ

directed to a direct isolate from a naturalන㔌‛‫ޔ‬ᄤὼ‛᧚ᢱ߆ࠄߩන㔌‛ߦ᭴ㅧ

product material, a product structurally based⊛ߦၮߠߊᚑᨐ‛‫ޔ‬ᄤὼ‛᧚ᢱ߇㊀ⷐߥ

upon an isolate from the natural product㐿⊒࡝࡯࠼ߣߥߞߚวᚑ᧚ᢱ‫ޔ‬㨇⾗Ḯឭmaterial, a synthetic material for which theଏ࿖㨉෶ߪ㨇SCO㨉߇ឭଏߒߚวᚑൻ

natural product material provided a keyว‛ߩᵷ↢‛‫ޔ‬෶ߪ೨ㅀߩන㔌‛‫ޔ‬ᚑᨐ

development lead, a derivative of a synthetic‛‫᧚ޔ‬ᢱ߽ߒߊߪᵷ↢‛ߩวᚑᣇᴺ߽ߒ

compound provided by [Source Country] orߊߪ೑↪ᣇᴺࠍኻ⽎ߣߔࠆ⊒᣿ߦ‫ߣ߭ޔ‬[SCO], or a method of synthesis or use of anyߒߊㆡ↪ߔࠆ߽ߩߣߔࠆ‫ޔߒߛߚޕ‬ᡰᛄ

aforementioned isolate, product, material or㊄ߣߒߡขࠅ᳿߼ࠆࡠࠗࡗ࡝࠹ࠖ࡯ߩ

derivative; though the percentage of royaltiesഀวߪ‫⵾ޔ‬ㅧ⽼ᄁߔࠆක⮎ຠߣᦨೋߩන

negotiated as payment might vary depending㔌‛ߣߩ㑐ଥߦᔕߓߡ⇣ߥࠅᓧࠆ‫ޕ‬ක⮎

upon the relationship of the marketed drug toຠ߇ᦨ⚳⊛ߦ⵾ㅧ⽼ᄁᲑ㓏ߦ⥋ࠆࡊࡠthe originally isolated product. It is࠮ࠬߪ‫ޔ‬10㨪15 ᐕࠍⷐߔࠆ㐳ᦼߩࡊࡠunderstood that the eventual development of a࠮ࠬߢ޽ࠆߎߣ߇ੌ⸃ߐࠇߡ޿ࠆ‫ޕ‬drug to the stage of marketing is a long term
process which may require 10-15 years.

13) ࡜ ࠗ ࠮ ࡦ ࠪ ࡯ ߩ ₪ ᓧ ߦ ᒰ ߚ ࠅ ‫ޔ‬13) In obtaining licensees, DTP/NCI/NIH will
require the applicant for license to seek as its

DTP/NCI ߪ‫ޔ‬NIH/OTT ߇࡜ࠗ࠮ࡦࠬ

↳⺧⠪ߦኻߒ‫ޔ‬㨇⾗Ḯឭଏ࿖㨉߆ࠄ౉ᚻfirst source of supply the natural products
available from [Source Country]. If noߢ߈ࠆᄤὼ‛ࠍ╙৻ߩଏ⛎Ḯߣߔࠆࠃ

appropriate licensee is found who will use߁⟵ോઃߌࠆߎߣࠍ‫ߔߣߩ߽ࠆߔ⺧ⷐޔ‬

natural products available from [Sourceࠆ‫ޕ‬㨇⾗Ḯឭଏ࿖㨉߆ࠄ౉ᚻߢ߈ࠆᄤὼ

Country], or if [SCO] or their suppliers cannot‛ࠍ೑↪ߔࠆㆡᒰߥ࡜ࠗ࠮ࡦࠪ࡯߇޿

provide adequate quantities of raw materials atߥ޿႐ว‫ޔ‬෶ߪ㨇SCO㨉߽ߒߊߪߘߩ

a mutually agreeable fair price, the licensee willଏ⛎⠪߇ㆡಾߥ㊂ߩේ᧚ᢱࠍ⋧੕ߦว

be required to pay to the [Source Country]ᗧߢ߈ࠆ౏ᱜߥଔᩰߢឭଏߢ߈ߥ޿႐

Government or [SCO] as appropriate,ว‫ޔߪߦ࡯ࠪࡦ࠮ࠗ࡜ޔ‬ㆡቱ㨇⾗Ḯឭଏ

compensation (to be negotiated) to be used for࿖㨉ߩ᡽ᐭ෶ߪ㨇SCO㨉ߦኻߒ‫⛘ޔ‬Ṍ

expenses associated with cultivation ofߩ߅ߘࠇߩ޽ࠆ⮎↪↢‛ߩᩱၭ⢒ᚑߦ

medicinal organisms that are endangered or for઻߁⾌↪෶ߪߘߩઁߩㆡಾߥ଻ోភ⟎other appropriate conservation measures.

ߦలᒰߔࠆߚ߼‫⵬ޔ‬ఘ㧔㊄㗵ߪ੤ᷤߦࠃ

These terms will also apply in the event thatࠆ㧕ࠍᡰᛄ߁ࠃ߁⟵ോઃߌࠆ߽ߩߣߔ

the licensee begins to market a syntheticࠆ‫ޕ‬ᒰ⹥᧦ઙߪ‫ޔ߇࡯ࠪࡦ࠮ࠗ࡜ޔ‬㨇⾗

material for which a material from [SourceḮឭଏ࿖㨉߆ࠄߩ᧚ᢱ߇㊀ⷐߥ㐿⊒࡝࡯Country] provided a key development lead.

࠼ߣߥߞߚวᚑ᧚ᢱߩ⵾ㅧ⽼ᄁࠍ㐿ᆎߔࠆ႐วߦ߽‫ޔ‬ㆡ↪ߔࠆ߽ߩߣߔࠆ‫ޕ‬14) Article 13 shall not apply to organisms which14) ╙ 13 ᧦ߪ‫ߩઁޔ‬࿖‫౉ߦ↱⥄߽ࠄ߆ޘ‬ᚻare freely available from different countriesߢ߈ࠆ↢‛㧔ߔߥࠊߜ৻⥸⊛ߥ㔀⨲‫ޔ‬ㄘ

(i.e., common weeds, agricultural crops,૞‛‫↪⾨ⷰޔ‬ᬀ‛‫ޔ‬ઃ⌕↢‛㧕ߦߪㆡ↪

ornamental plants, fouling organisms) unlessߒߥ޿߽ߩߣߔࠆ߇‫ޔߒߛߚޔ‬ᒰ⹥↢‛

information indicating a particular use of theߩ․ቯߩ↪ㅜ㧔଀߃߫⮎↪‫ޔ‬Ვ⯻↪ߥߤ㧕organism (e.g., medicinal, pesticidal) wasࠍ␜ߔᖱႎ߇‫ޔ‬㨇⾗Ḯឭଏ࿖㨉ߦ߅ߌࠆprovided by local residents to guide theߘߩ↢‛ߩណ㓸ࠍ᩺ౝߒߚ⃻࿾૑᳃ߦcollection of such an organism from [Sourceࠃߞߡឭଏߐࠇߚ႐ว‫ޔ‬෶ߪ㨇SCO㨉

Country], or unless other justification

ߣ DTP/NCI ߩ෺ᣇߦߣߞߡฃߌ౉ࠇࠄ

acceptable to both [SCO] and DTP/NCI isࠇࠆᅷᒰߥℂ↱߇␜ߐࠇࠆ႐วߦߪ‫ߎޔ‬

provided. In the case where an organism isߩ㒢ࠅߢߪߥ޿‫ߩઁޕ‬࿖‫౉ߦ↱⥄ࠄ߆ޘ‬freely available from different countries, but aᚻߢ߈ࠆ↢‛ߢ޽ߞߡ߽‫ޔ‬ᵴᕈ‛⾰ࠍ↥

phenotype producing an active agent is found↢ߔࠆ⴫⃻ဳ߇㨇⾗Ḯឭଏ࿖㨉ߢߩߺ⷗

only in [Source Country], Article 13 shall apply.

ࠄࠇࠆ႐วߦߪ‫ ╙ޔ‬13 ᧦ࠍㆡ↪ߔࠆ߽ߩߣߔࠆ‫ޕ‬15) Publication of data resulting from the15) ᧄੌ⸃ⷡᦠߦၮߠߊද௛߆ࠄᓧࠄࠇߚ

collaboration under this MOU will be࠺࡯࠲ߩ౏⴫ߪ‫ޔ‬
㨇SCO㨉ߣ DTP/NCI

undertaken at times determined by agreementߣߩ㑆ߩวᗧߦࠃࠅቯ߼ࠆᤨὐߢⴕ߁

between [SCO] and DTP/NCI. Before either߽ߩߣߔࠆ‫ߩ߆ࠇߕ޿ޕ‬ᒰ੐⠪߇౏⴫ߩparty submits a paper or abstract forߚ߼ߦ⺰ᢥ෶ߪⷐ⚂ࠍឭ಴ߔࠆ႐วߦ

publication, the other party shall have sixty (60)ߪ‫ߩߘޔ‬೨ߦ⋧ᚻᣇᒰ੐⠪ߦኻߒ‫ࡆ࡟ޔ‬

days to review and as necessary, file a patentࡘ࡯ࠍⴕ޿෸߮ᔅⷐߦᔕߓߡ╙ 9 ᧦ߦ

application in accordance with Article 9.

ᓥߞߡ․⸵ࠍ಴㗿ߔࠆߚ߼ߩᦼ㑆ߣߒߡ‫ޔ‬60 ᣣ㑆ࠍਈ߃ࠆ߽ߩߣߔࠆ‫ޕ‬16) It is the intention of NCI that [SCO] not beliable to DTP/NCI for any claims or damages16) 㨇SCO㨉߆ࠄឭଏߐࠇߚ᧚ᢱࠍ NCI ߇೑↪ߒߚߎߣ߆ࠄ↢ߓࠆ޿߆ߥࠆ⺧᳞

arising from NCI’s use of the material provided෶ ߪ ៊ ኂ ߦ ߟ ޿ ߡ ߽ ‫ޔ‬㨇 SCO 㨉 ߇by [SCO]; however, no indemnification for any

DTP/NCI ߦኻߒߡ⽿છࠍ⽶߁ߴ߈ߢߪ

loss, damage, or liability is intended or provided

ߥ޿ߣ޿߁ߩ߇ NCI ߩ⠨߃ߢ޽ࠆ‫ߚޕ‬by any party under this MOU. Each partyߛߒᧄੌ⸃ⷡᦠߦ߅޿ߡߪ‫ࠆߥ߆޿ޔ‬ᒰ

shall be liable for any loss, claim, damage or੐⠪߽៊ᄬ‫៊ޔ‬ኂ෶ߪ⽿છߦኻߒߡ⵬ఘ

liability, that said party incurs, as a result ofߔࠆᗧ࿑ߪߥߊ‫⵬ߚ߹ޔ‬ఘߔࠆߎߣ߽ߥ

said party’s activities under this MOU, except޿‫ޕ‬ฦ‫ߩޘ‬ᒰ੐⠪ߪ‫ߦᦠⷡ⸃ੌᧄޔ‬ၮߠthat the NCI, as an agency of the United States,ߊ⥄Ꮖߩᵴേߩ⚿ᨐߣߒߡ⥄ࠄ߇ⵍࠆassumes liability only to the extent as provided

৻ಾߩ៊ᄬ‫⺧ޔ‬᳞‫៊ޔ‬ኂ෶ߪ⽿છߦኻߒunder the Federal Tort Claim Act (28 U.S.C.

ߡ⽿છࠍ⽶߁߽ߩߣߔࠆ߇‫ޔߒߛߚޔ‬§171).

NCI ߇‫☨ޔ‬࿖ߩ৻ᯏ㑐ߣߒߡ‫ޔ‬ㅪ㇌ਇ
ᴺⴕὑ⺧᳞ᴺ㧔28 U.S.C. § 171㧕ߩⷙቯߔࠆ▸࿐ౝߦ㒢ߞߡ⽿છࠍ⽶߁႐วߪ㒰ߊ‫ޕ‬17) DTP/NCI and its relevant contractors will not17) DTP/NCI ෸߮ߘߩᆔ⸤ᬺോࠍⴕ߁⠪distribute materials provided by [SCO] to otherߪ‫ޔ‬㨇SCO㨉߇ឭଏߒߚ᧚ᢱࠍ㨇SCO㨉

organizations without written authorizationߩᦠ㕙ߦࠃࠆ⸵นߥߒߦઁߩ⚵❱ߦ㈩from [SCO]. However, should [SCO] wish toᏓߒߡߪߥࠄߥ޿‫ߒߛߚޕ‬㨇SCO㨉߇‫ޔ‬consider collaboration with organizations

NCI ߩណ㓸ᄾ⚂ࠍㅢߓߡขᓧߒߚ᧚ᢱ

selected by NCI for distribution of materials

ߩ㈩Ꮣߦߟ޿ߡ‫ޔ‬NCI ߇ㆬቯߒߚ⚵❱acquired through NCI collection contracts,ߣߩද௛ࠍᬌ⸛ߒߚ޿ߣ⠨߃ࠆ႐ว‫ޔ‬

DTP/NCI will establish contact between such

DTP/NCI ߪᒰ⹥⚵❱ߣ㨇SCO㨉ߣߩખ

organizations and [SCO].

੺ࠍⴕ߁߽ߩߣߔࠆ‫ޕ‬18) [SCO] scientists and their collaborators may
screen additional samples of the same materials18) 㨇SCO㨉ߩ⑼ቇ⠪෸߮ߘߩද௛⠪ࠄߪ‫ޔ‬ᧄੌ⸃ⷡᦠߣߪ㑐ଥߥߊ‫‛↢ߩઁޔ‬ᵴᕈfor other biological activities and develop themࠍត⚝ߔࠆߚ߼ᒰ⹥᧚ᢱߩㅊട⹜ᢱࠍ

for such purposes independently of this MOU.

ࠬࠢ࡝࡯࠾ࡦࠣߔࠆߎߣ߇ߢ߈‫ޔ‬ᒰ⹥⋡⊛ߢߘࠇࠄࠍ㐿⊒ߔࠆߎߣ߇ߢ߈ࠆ‫ޕ‬19) With the exception of Articles 1-4 and 6, all19) ╙ 1 ᧦߆ࠄ 4 ᧦‫ޔ‬෸߮ 6 ᧦ࠍ㒰߈‫ઁޔ‬other Articles shall survive the expiration ofߩߔߴߡߩ᧦㗄ߪᧄੌ⸃ⷡᦠߩᦼ㒢ḩ

this Agreement or its termination by theੌ‫ޔ‬෶ߪ㨇⾗Ḯឭଏ࿖㨉߽ߒߊߪ㨇SCO㨉

[Source Country] or [SCO]. Subsequentߦࠃࠆ⚳ੌߩᓟ߽ሽ⛯ߔࠆ߽ߩߣߔࠆ‫ޕ‬

compounds and/or extracts may be submittedએᓟߩൻว‛෸߮/෶ߪ᛽಴‛ߪ‫ޔ‬ㆡᒰunder the appropriate DTP/NCI mechanism

ߥ DTP/NCI ߩ೙ᐲ෸߮දቯߦၮߠ޿ߡ

and agreement.

ឭ಴ߔࠆߎߣ߇ߢ߈ࠆ‫ޕ‬This MOU shall be valid as of the date of the final

ᧄੌ⸃ⷡᦠߪ⟑ฬᮭ⠪ߦࠃࠆਅ⸥ߩᦨ⚳⟑authorized signature below for an initial period ofฬᣣࠍ߽ߞߡ⊒ലߒ‫ޔ‬ᒰೋ 5 ᐕ㑆᦭ലߣߥ

five (5) years, after which, it can be renewed byࠆ߽ߩߣߒ‫ߩߘޔ‬ᓟߪ⋧੕ߩวᗧߦࠃࠅᦝᣂ

mutual agreement. It may be amended at anyߔࠆߎߣ߇ߢ߈ࠆ‫ޔߪᦠⷡ⸃ੌᧄޕ‬ਔᒰ੐⠪time subject to the written agreement of bothߩᦠ㕙ߦࠃࠆหᗧࠍᓧࠆߎߣࠍ᧦ઙߣߒߡ‫ޔ‬

parties. Copies of such amendments will be kept㓐ᤨ‫ୃޔ‬ᱜߔࠆߎߣ߇ߢ߈ࠆ‫ޕ‬ᒰ⹥ୃᱜ ߪ

on file at both of the addresses indicated below.

ਅ⸥ߦ␜ߔ෺ᣇߩ૑ᚲߦ߅޿ߡࡈࠔࠗ࡞ߦ

[SCO] and DTP/NCI are confident that this MOU଻▤ߔࠆ߽ߩߣߔࠆ‫ޕ‬
㨇SCO㨉ߣ DTP/NCI

will lay the basis for a mutually successfulߪ‫ߩࡦࠟޔ߇ᦠⷡ⸃ੌᧄޔ‬ᣂߚߥᴦ≮ᴺߩ⊒

cooperation in discovering and developing new⷗෸߮㐿⊒㕙ߢ෺ᣇߦߣߞߡታࠅ޽ࠆදജ

therapies in the treatment of cancer.

ߩၮ␆ࠍ▽ߊ߽ߩߣ⏕ାߒߡ޿ࠆ‫ޕ‬For the [SCO]:

For the National Cancer
Institute:㨇SCO㨉࿖┙≸⎇ⓥᚲ

__________________________
Director, National
Cancer Institute________________________________
࿖┙≸⎇ⓥᚲᚲ㐳_____________
Date_____________
Date________________
ᣣઃ________________
ᣣઃ

mailing andcontact address:

mailing andcontact address:ㇷㅍ෸䈶ㅪ⛊వ૑ᚲ䋺㩷 ㇷㅍ෸䈶ㅪ⛊వ૑ᚲ䋺㩷㩷

Technology Transfer
BranchNational Cancer
Institute at Frederick
NCI-Frederick
Fairview Center, Suite
500 1003 - W. 7th Street
Frederick, MD
21701-8512
Telephone: 301-846-5465
Facsimile: 301-846-6820㩷

Technology Transfer
BranchNational Cancer
Institute at Frederick
NCI-Frederick
Fairview Center, Suite
500 1003 - W. 7thStreet Frederick, MD
21701-8512
㔚⹤: 301-846-5465
Fax: 301-846-6820㩷

一般財団法人 バイオインダストリー協会〒104-0032 東京都中央区八丁堀2-26-9 グランデビルディング8F
TEL：03-5541-2731 FAX：03-5541-2737
発行日：2013 年3 月 1 日